본문으로 건너뛰기
← 뒤로

Adaptive therapy for perioperative non-small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment.

1/5 보강
Translational oncology 2026 Vol.64() p. 102660
Retraction 확인
출처

Xie LJ, Fu LL, Liu SC, Bai CS, Xu BC, He XW, Lin HF, Zeng YC, Tang WJ

📝 환자 설명용 한 줄

Lung cancer remains the leading cause of cancer incidence and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for about 85% of cases.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Xie LJ, Fu LL, et al. (2026). Adaptive therapy for perioperative non-small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment.. Translational oncology, 64, 102660. https://doi.org/10.1016/j.tranon.2025.102660
MLA Xie LJ, et al.. "Adaptive therapy for perioperative non-small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment.." Translational oncology, vol. 64, 2026, pp. 102660.
PMID 41496417

Abstract

Lung cancer remains the leading cause of cancer incidence and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for about 85% of cases. The low rate of early diagnosis and the high rate of occult metastases limit the survival benefits of conventional treatments. The current TNM staging system fails to fully reflect tumor heterogeneity or the dynamic molecular evolution of the disease, thus affecting the prediction of recurrence and the prognostic stratification. Some recent advances in minimal residual disease (MRD) detection, such as ultra-sensitive liquid biopsy technologies, have largely overcome the limitations of traditional imaging and offered a transformative approach for continuous, precision-based management of lung cancer. This review systematically summarized the technological evolution of MRD detection and highlighted its clinical significance in guiding adaptive therapy for NSCLC, including treatment escalation, de-escalation, and the emerging concept of precision-guided drug holidays. Moreover, the authors comprehensively discussed the "Four-Dimensional TNMB Staging System," which incorporates continuous molecular monitoring to address the static limitations of conventional staging and enhance the accuracy of prognostic stratification. Although ongoing challenges, such as the lack of standardized interpretation criteria and limited detection sensitivity, the combinations with the third-generation liquid biopsy platforms, multi-omics analyses, and multi-center prospective validation studies are expected to advance the clinical implementation of MRD-guided strategies. The paradigm change will enable the transition of NSCLC management from conventional standardized models to a precision-guided, closed-loop system of "monitoring-intervention-remonitoring," establishing a solid theoretical and practical foundation for comprehensive, molecularly driven management strategies.